Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis

Apoptosis. 2005 Dec;10(6):1369-81. doi: 10.1007/s10495-005-1511-1.

Abstract

We have undertaken a study to characterize the lipolytic pathway responsible for the generation of free fatty acids (FFA) during Fas/CD95-induced apoptosis in Jurkat cells. It was initially shown that the cellular lipid fraction that suffered the major quantitative decrease during Fas-induced apoptosis was that of phosphatidylcholine (PC). In addition, the secretion of palmitic acid-derived FFA was largely prevented by D609, an inhibitor of PC-specific phospholipase C (PC-PLC) and also by the diacylglycerol lipase (DAGL) inhibitor RHC-80267, suggesting that the secretion of these FFA during Fas-induced apoptosis is mediated by the generation of DAG by a PC-PLC activity and, sequentially, by a 1-DAGL activity which generates the FFA from its sn-1 position. The endocannabinoid 2-arachidonoyl glycerol (2-AG) should be generated as a sub-product of this pathway, but it did not accumulate inside the cells nor was secreted into the supernatant. Interestingly, the complete inhibition of free AA secretion during Fas-induced apoptosis was only achieved by using the AA trifluoromethylketone, which not only inhibits all types of phospholipase-A(2) (PLA(2)) activities, but also the described lytic activities on 2-AG. Using a combination of RHC-80267 and the iPLA(2)-specific inhibitor bromoenol lactone, it was shown that the DAGL pathway also cooperates with iPLA(2) in the generation of free arachidonate.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis* / drug effects
  • Arachidonic Acids / pharmacology
  • Bridged-Ring Compounds / pharmacology
  • Cyclohexanones / pharmacology
  • Endocannabinoids
  • Enzyme Inhibitors / pharmacology
  • Fatty Acids, Nonesterified / metabolism*
  • Glycerides / pharmacology
  • Humans
  • Jurkat Cells
  • Ketones / pharmacology
  • Lipid Metabolism / drug effects
  • Lipolysis* / drug effects
  • Lipoprotein Lipase / antagonists & inhibitors
  • Models, Biological
  • Norbornanes
  • Palmitic Acid / pharmacology
  • Phosphatidic Acids / metabolism
  • Phosphatidylcholines / metabolism
  • Thiocarbamates
  • Thiones / pharmacology
  • Type C Phospholipases / antagonists & inhibitors
  • fas Receptor / metabolism*

Substances

  • 11-hexadecenyl trifluoromethyl ketone
  • Arachidonic Acids
  • Bridged-Ring Compounds
  • Cyclohexanones
  • Endocannabinoids
  • Enzyme Inhibitors
  • Fatty Acids, Nonesterified
  • Glycerides
  • Ketones
  • Norbornanes
  • Phosphatidic Acids
  • Phosphatidylcholines
  • Thiocarbamates
  • Thiones
  • fas Receptor
  • Palmitic Acid
  • tricyclodecane-9-yl-xanthogenate
  • 1,6-bis(cyclohexyloximinocarbonyl)hexane
  • glyceryl 2-arachidonate
  • Lipoprotein Lipase
  • Type C Phospholipases